mXELOXIRI Combined With Molecular Targeted Drug in mCRC
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The objective is to evaluate the efficacy and safety of modified XELOXIRI combined with
molecular targeted drug as first-line therapy in patients with metastatic colorectal cancer
(mCRC)